PLYGF (PolyPeptide Group AG) Risk Assessment


PLYGF PolyPeptide Group AG PLYGF
61 GF Score
Price $43.00
GF Value $40.58
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of PolyPeptide Group AG is: Moderate Risk: Sensitive, better choose undervalued stock.

PolyPeptide Group AG  (OTCPK:PLYGF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

PolyPeptide Group AG Risk Assessment Related Terms

PLYGF vs ZTS, UTHR, VTRS: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PolyPeptide Group AG Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Risk Assessment distribution charts can be found below:

* The bar in red indicates where PolyPeptide Group AG's Risk Assessment falls into.


PLYGF
61GF Score
PolyPeptide Group AG PLYGF
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of $43.00 is trading 6% above its estimated GF Value™ of $40.58. GuruFocus considers PolyPeptide Group AG to be Fairly Valued.

Key valuation signals for PLYGF:

  • Risk Assessment:
  • GF Value™: $40.58 vs. price of $43.00 (6% above fair value)
  • GF Score™: 61/100 with 8 warning signs

No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
61GF Score

Get the complete analysis for PLYGF

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.00
Price
$40.58
GF Value